Overview

Toxicity/Benefit Ratio Optimization of Chemotherapy in Colorectal Cancer (CRC) Patients by Determination of Individual Genotypic Determinants

Status:
Completed

Trial end date:
2008-12-01

Target enrollment:

Participant gender:

Summary

This study intends to optimize a fluorouracil/irinotecan chemotherapy regimen by the identification of individual thymidylate synthase (TS) and UDP-glucuronosyltransferase 1 (UGT1A1) polymorphisms before the first administration. The results of this identification determine the chemotherapy type: high-dose irinotecan or not.

Phase:

Phase 4

Details

Lead Sponsor:

Institut de Recherche Clinique sur les Cancers et le Sang

Collaborator:

Pfizer

Treatments:

Fluorouracil
Irinotecan